COVID-19

The association of obesity-related traits on COVID-19 severity and hospitalization is affected by socio-economic status: a multivariable Mendelian randomization study

Brenda Cabrera-Mendoza,1,2 Frank R Wendt,1,2 Gita A Pathak,1,2 Flavio De Angelis,1,2 Antonella De Lillo,1 Dora Koller1,2 and Renato Polimanti 1,2*

1Department of Psychiatry, Yale School of Medicine, West Haven, CT, USA and 2VA CT Healthcare System, West Haven, CT, USA

*Corresponding author. Department of Psychiatry, Yale University School of Medicine, VA CT 116A2, 950 Campbell Avenue, West Haven, CT 06516, USA. E-mail: renato.polimanti@yale.edu

Revised 18 October 2021; Editorial decision 22 May 2022; Accepted 30 May 2022

Abstract

Background: Due to its large impact on human health, socio-economic status (SES) could at least partially influence the established association between obesity and coronavirus disease 2019 (COVID-19) severity. To estimate the independent effect of body size and SES on the clinical manifestations of COVID-19, we conducted a Mendelian randomization (MR) study.

Methods: Applying two-sample MR approaches, we evaluated the effects of body mass index (BMI, n = 322 154), waist circumference (WC, n = 234 069), hip circumference (n = 213 019) and waist–hip ratio (n = 210 088) with respect to three COVID-19 outcomes: severe respiratory COVID-19 (cases = 8779, controls = 1 000 875), hospitalized COVID-19 (cases = 17 992, controls = 1 810 493) and COVID-19 infection (cases = 87 870, controls = 2 210 804). Applying a multivariable MR (MVMR) approach, we estimated the effect of these anthropometric traits on COVID-19 outcomes accounting for the effect of SES assessed as household income (n = 286 301).

Results: BMI and WC were associated with severe respiratory COVID-19 [BMI: odds ratio (OR) = 1.51, CI = 1.24–1.84, P = 3.01e-05; WC: OR = 1.48, 95% CI = 1.15–1.91, P = 3.72e-05]. Conversely, income was associated with lower odds of severe respiratory (OR = 0.70, 95% CI = 0.53–0.93, P = 0.015) and hospitalized COVID-19 (OR = 0.78, 95% CI = 0.66–0.92, P = 0.003). MVMR analyses showed that the effect of these obesity-related traits on increasing the odds of COVID-19 negative outcomes becomes null when accounting for income. Conversely, the association of income with lower odds of COVID-19 negative outcomes is not affected when including the anthropometric traits in the multivariable model.

© The Author(s) 2022; all rights reserved. Published by Oxford University Press on behalf of the International Epidemiological Association
Conclusion: Our findings indicate that SES contributes to the effect of obesity-related traits on COVID-19 severity and hospitalization.

Key words: COVID-19, obesity, socio-economic status, Mendelian randomization

Key Messages
- Obesity is one of the main factors associated with severe manifestations of coronavirus disease 2019 (COVID-19).
- Due to its large impact on human health, socio-economic status (SES) could influence the association between obesity and COVID-19 severity.
- Our results indicate that the association between obesity and severe manifestations of COVID-19 is affected by the effect of SES.
- SES association with COVID-19 outcomes is not affected by obesity-related traits.
- Preventive strategies targeting body size to reduce COVID-19 morbidity and mortality could benefit from assessing the SES context.

Introduction

The coronavirus disease 2019 (COVID-19) resulting from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has caused a pandemic since early 2020.1 As of April of 2022, this pandemic has led to ~502 million COVID-19 cases and >6.19 million deaths worldwide.2 The clinical manifestations of COVID-19 vary from asymptomatic infection to a critical illness, i.e. respiratory failure, septic shock and/or multiple organ dysfunctions.3,4 Obesity appears to be one of the main factors associated with severe manifestations of COVID-19.5–8 Leveraging genetic information, few studies conducted causal inference analyses, showing that body mass index (BMI) and other body measure traits have a putative causal effect on severe and critical COVID-19 illness.9–11 However, to our knowledge, no investigation has been conducted to verify whether the association of body composition with COVID-19 outcomes was affected by socio-economic status (SES). SES has a large impact on many dimensions of health with individuals with poor SES presenting high morbidity and low life expectancy.12,13 There is consistent evidence of the impact of SES traits on obesity-related anthropometric traits, such as BMI.14,15 For example, higher levels of material deprivation have been associated with a higher BMI.16 Also, higher income has been associated with a higher BMI in developing countries, whereas in developed countries, BMI has been found to be correlated inversely with median household income.17 A causal inference analysis based on genetic information showed that BMI may affect social and SES outcomes, but there is also evidence of horizontal pleiotropy (i.e. shared pathways) between these traits.14

There is a growing literature showing consistently that SES is a primary predictor across COVID-19 outcomes, ranging from infection to mortality.18,19 Due to its clinical implication, it is important to understand whether the relationship between body size and COVID-19 is affected by their associations with SES. Mendelian randomization (MR) studies are a powerful tool to investigate the potential causative role of SES traits across the spectrum of human health.20–22 Accordingly, we conducted a MR study to assess the effect of traits related to body size and composition on COVID-19 outcomes, accounting for the effect of SES.

Methods

Data sources

In our study, we investigated the following anthropometric traits: BMI, waist circumference (WC), hip circumference (HIP) and waist–hip ratio (WHR). To assess the effect of body fat distribution, we also investigated BMI-adjusted anthropometric measures, i.e. BMI-adjusted WC, BMI-adjusted HIP and BMI-adjusted WHR. Genome-wide association studies (GWAS) statistics were derived from the meta-analyses performed by the Genetic Investigation of ANthropometric Traits (GIANT) consortium. This is an international collaboration aimed to identify genetic loci involved in human body size and shape.23 These GWAS were conducted in up to 322,154 participants of European descent. The cohorts and GWAS procedures for BMI (n = 322,154),24 WC (n = 234,069), WHR (n = 210,088), HIP (n = 213,019), BMI-adjusted WC (n = 234,069), BMI-adjusted HIP (n = 213,019) and BMI-adjusted WHR

International Journal of Epidemiology, 2022, Vol. 51, No. 5
(n = 2,100,880) have been previously described. The units of exposure of anthropometric traits were defined as follows: kilograms/metres² for BMI, centimetres (cm) for HIP, BMI-adjusted HIP, WC and BMI-adjusted WC. We selected the 2015 versions of the GIANT GWAS meta-analyses because they do not include UK Biobank cohort, which is a contributor to the COVID-19 data described below and could bias causal inference effect estimates.

We evaluated three COVID-19 outcomes: severe respiratory COVID-19, hospitalized COVID-19 and COVID-19 infection. These data were derived from Release 6 of the GWAS meta-analysis conducted by the COVID-19 Host Genetics Initiative (HGI). This is an international genetics collaboration that aims to uncover the genetic determinants of COVID-19 susceptibility, severity and outcomes. For the evaluated COVID-19 outcomes, controls were genetically ancestry-matched individuals without SARS-CoV-2 infection. In our analyses, we used GWAS summary statistics from the comparison between cases and control groups of each exposure. The severe respiratory COVID-19 outcome resulted from the comparison between patients with very severe respiratory failure secondary to COVID-19 (n = 8,779) vs controls (n = 1,001,875). The hospitalized COVID-19 data were generated from the comparison of patients with a laboratory-confirmed SARS-CoV-2 infection that were hospitalized due to COVID-19 symptoms (n = 17,992) vs controls (n = 1,810,493). Finally, the COVID-19 infection analysis was conducted comparing 87,870 individuals reporting SARS-CoV-2 infection with 2,210,804 controls. Information regarding SARS-CoV-2 infection was derived from a laboratory test, electronic health record, clinically confirmed COVID-19 and self-reported COVID-19 (e.g. by questionnaire).

Analysed data were generated from only European-descent individuals to avoid potential population stratification biases in the hospitalized COVID-19 and COVID-19 infection outcomes. However, for the severe respiratory COVID-19 outcome, European specific data were not available. Thus, the analysis for this COVID-19 outcome was conducted using the data generated from a multi-ancestry GWAS meta-analysis. Although the majority of the patients were of European descent (~80% of the effective sample size), we used data from Release 5 of the COVID-19 HGI GWAS meta-analysis including only European-descent individuals (5,101 cases vs 1,383,241 controls) to verify the results generated from the Release 6 data. Of note, the analysed data do not include data from 23andMe samples when COVID-19 phenotypes were tested as outcome in the MR analyses.

To investigate the effect of SES, we analysed genetic data related to self-reported household income information from UK Biobank participants, hereinafter referred to as income. Income refers to the combined gross income of all members of a household and was assessed via the touchscreen questionnaire completed by UK Biobank participants. This information was collected using a five-point scale corresponding to the total household income before tax, 1 being ≤£18,000, 2 being £18,000–£29,999, 3 being £30,000–£51,999, 4 being £52,000–£100,000 and 5 being >£100,000. Genome-wide association statistics were obtained from a previous income GWAS conducted in 286,301 individuals of European descent. The GWAS procedure is described in previously published reports.

MR

MR is an analytic technique to estimate the effect of an exposure on an outcome of interest. MR uses genetic variants, which are fixed at conception, to support causal inferences about the effects of risk factors, as they are unlikely to be affected by reverse causation, as they temporally precede the outcome, and confounding factors that act after conception. MR is based on three assumptions: (i) the genetic instruments are associated with the outcome of interest; (ii) the genetic instruments are not associated with potential confounders of the risk factor–outcome association; and (iii) the genetic instruments affect the outcome only through their effect on the risk factor.

We estimated the putative causal effect of anthropometric traits on COVID-19 phenotypes using a two-sample MR approach. Leveraging information from genome-wide association statistics, we can estimate the putative causal effect of the exposure on the outcome, which represents the sum of all possible paths from the exposure to the outcome. This analysis was conducted using the R package TwoSampleMR. For each anthropometric trait, we defined a genetic instrument based on genome-wide significant variants (P < 5 × 10⁻⁸) that were linkage disequilibrium (LD)-independent (r² < 0.001 within a 10,000-kilobase window) based on the 1000 Genomes Project Phase 3 reference panel for European populations. Also, we excluded those genetic variants that were not present in the COVID-19 outcome GWAS data sets. For each MR test performed, we estimated R² that corresponds to the proportion of variance of the exposure explained by the single-nucleotide polymorphism (SNPs) and mean F-statistic to evaluate the strength of the genetic instruments.

Our primary MR analysis was conducted using the inverse-variance weighted (IVW) approach, because it provides the highest statistical power. As a secondary analysis, we also used MR–Egger, weighted median, simple mode and weighted mode. Although the performance is...
not comparable to the IVW, these methods can account for certain violations of the MR assumptions due to different pleiotropy scenarios.\(^{38}\) Accordingly, we evaluated the concordance of the effect direction observed with the IVW approach with those generated using the other MR methods investigated.

Additionally, the presence of horizontal pleiotropy and heterogeneity within the genetic instruments, which are potential confounders in MR analyses, was tested using MR–Egger regression intercept\(^{39}\) and IVW and MR–Egger heterogeneity tests\(^{40}\) respectively. Furthermore, outliers contributing to the heterogeneity (variability in the causal estimates obtained for each SNP) and horizontal pleiotropy (the variant affects the disease indirectly, i.e. outside its effect on the exposure) within the genetic instruments were identified by leave-one-out analyses and the visual assessment of forest and funnel plots. The genetic variants identified as outliers were removed from the analysis and the causal estimates were recalculated to evaluate the potential biases generated by these outliers in the MR results. Similarly to other MR studies,\(^{21,41,42}\) we avoided inference based simply on \(P\)-value thresholds. The direction and strength of effect for each MR association, together with the corresponding \(P\)-value, was considered to better reflect the spectrum of evidence related to these results.\(^43\) For all continuous exposures, i.e. anthropometric traits and income, exposure effects on their respective outcomes were calculated as odds ratio (OR) for the outcome per one standard deviation (SD) increase in each exposure. Whereas for binary exposures, i.e. COVID-19 phenotypes, exposure effects on their respective outcome were calculated as beta estimates that represent one unit increase in the outcome risk per additional copy of the effect allele.

To verify the presence of a bidirectional relationship between the anthropometric traits and COVID-19 outcomes, we defined genetic instruments based on genome-wide significant variants \((P<5\times10^{-8})\) using the same procedure as described above. However, because the number of variants under these criteria was relatively low (six or seven SNPs), we also evaluated an alternative approach based on the inclusion of all LD-independent variants available from the top 10,000 variants released from the COVID HGI meta-analysis including 23andMe data. In this large data set, COVID-19 was investigated in 8779 cases and 1,001,875 controls for the COVID-19 phenotype; 24,274 cases and 2,061,529 controls for the hospitalized COVID-19 phenotype; and 112,612 cases and 2,474,079 controls for the COVID-19 infection phenotype. However, due to 23andMe data-sharing restrictions, genetic association statistics are available only for the top 10,000 variants, i.e. variants with the highest association with each COVID-19 outcome. Accordingly, we extracted the LD-independent loci among them and used this information to define suggestive genetic instruments for the COVID-19 outcomes investigated. These suggestive genetic instruments including variants not reaching genome-wide significance might lead to the violation of the MR assumptions. Thus, we considered the estimates obtained from the IVW method and the MR–Robust Adjusted Profile Score (MR–RAPS) approach as well.\(^{44}\) The MR–RAPS approach estimates the causal effect under pervasive horizontal pleiotropy and is robust to occasional outliers and weak genetic instruments.\(^{44}\) The reliability of the findings was tested using multiple sensitivity analyses described above.

Then, we estimated the putative causal effect of income on anthropometric traits and vice versa using the univariable MR procedure described above. The genetic instruments in both analyses were genome-wide significant variants \((<5\times10^{-8})\) associated with each exposure. Then, we evaluated the direct causal effect of anthropometric traits on income using a multivariable MR (MVMR) analysis. After identifying the putative effects of anthropometric traits, we tested the putative effect of income on COVID-19 outcomes, applying the same analytic pipeline. The genetic instrument defined was then used to verify whether the association of anthropometric traits with COVID-19 outcomes is independent of the SES effect. Specifically, we tested the genetic instruments of anthropometric traits and income with respect to COVID-19 outcomes in a MVMR analysis. This is an extension of the standard MR framework to consider multiple potential risk factors in a single model and calculate the independent association of each risk exposure with the outcome.\(^{33,45,46}\)

The MVMR analysis was conducted using the MendelianRandomization R package.\(^45\) To graphically show the non-overlap of the SNPs for the exposures tested in the MVMR, we used ggVennDiagram R package.\(^47\)

**Results**

We observed consistent associations of anthropometric traits on COVID-19 outcomes (Figure 1). The strongest association was observed with respect to BMI and WC: a 1-SD increase in genetically determined BMI (kg/m\(^2\)) and WC (cm) was associated with increased odds of severe respiratory COVID-19 (BMI: \(\text{OR}=1.51, 95\% \text{CI}=1.24\text{--}1.84, P=3.01\text{e}\text{-}05\); WC: \(\text{OR}=1.48, 95\% \text{CI}=1.15\text{--}1.91, P=0.002\)) and hospitalized COVID-19 (BMI: \(\text{OR}=1.50, 95\% \text{CI}=1.32\text{--}1.72, P=8.83\text{e}\text{-}10\); WC: \(\text{OR}=1.41, 95\% \text{CI}=1.20\text{--}1.67, P=3.72\text{e}\text{-}05\)). Reduced effects were observed for these anthropometric traits with respect to COVID-19 infection (BMI: \(\text{OR}=1.07, 95\% \text{CI}=1.02\text{--}1.12, P=0.003\); WC:
OR = 1.12, 95% CI = 1.05–1.19, P = 1e-4). Also, a 1-SD increase in genetically determined HIP (cm) showed a positive association with severe respiratory COVID-19 (OR = 1.35, 95% CI = 1.09–1.67, P = 0.005), hospitalized COVID-19 (OR = 1.23, 95% CI = 1.08–1.41, P = 0.0016) and COVID-19 infection (OR = 1.05, 95% CI = 1.005–1.10, P = 0.029). Among the anthropometric traits related to body fat distribution (i.e. WHR and traits adjusted for BMI), a 1-SD increase in genetically determined BMI-adjusted HIP (cm) was associated with severe respiratory COVID-19 (OR = 1.24, 95% CI = 1.05–1.46, P = 0.0109), but not with hospitalized COVID-19 (OR = 1.07, 95% CI = 0.96–1.20, P = 0.20), and with COVID-19 infection (OR = 1.01, 95% CI = 0.97–1.05, P = 0.54). The IVW effect estimate was consistent with those estimated using all other MR methods and no heterogeneity or horizontal pleiotropy was observed within BMI, WC, HIP and BMI-adjusted HIP genetic instruments (Figure 1, Supplementary Table S1 and Supplementary Figures S2–S4, available as Supplementary data at IJE online). For the MR tests evaluating the effect of anthropometric traits on COVID-19 outcomes, the F-statistic ranged from 46.20 to 69.49, and $R^2$ ranged from 6.08e-07 to 0.47 (Supplementary Table S1, available as Supplementary data at IJE online). The overlap of the LD-independent SNPs associated with the assessed anthropometric traits is shown in Supplementary Figure S1 (available as Supplementary data at IJE online). The analysis performed using GWAS data generated from only European-descent individuals from the COVID-19 HGI Release 5 data showed similar effect estimates to those derived from the trans-ancestry GWAS meta-analyses in the COVID-19 HGI data Release 6 (Supplementary Table S2, available as Supplementary data at IJE online).

To verify whether the effects of BMI, WC, HIP and BMI-adjusted HIP on COVID-19 outcomes were independent of each other, we entered the genetic instruments in pairwise MVMR models (income and each anthropometric trait) and an all-trait-combined MVMR model (income and all anthropometric traits) testing each COVID-19 outcome. The effects observed in the univariate MR were null after accounting for the effect of other anthropometric traits in the MVMR analysis (Supplementary Table S3, available as Supplementary data at IJE online). We also tested the possible reverse association of COVID-19

---

**Figure 1** Results of the Mendelian randomization (MR) analysis testing the effect of genetically determined anthropometric traits and income on (a) severe respiratory coronavirus disease 2019 (COVID-19), (b) COVID-19 hospitalization and (c) COVID-19 infection. 95% confidence intervals are reported for the inverse variance weighted estimates. Estimates from secondary MR methods are reported for each MR test. Income, household income; BMI, body mass index; WC, waist circumference; HIP, hip circumference; WHR, waist–hip ratio.
outcomes on the anthropometric traits (Supplementary Figure S5, available as Supplementary data at IJE online). The univariable MR analysis based on genetic instruments considering genome-wide significant variants showed null effects ($\beta_{\text{Severe respiratory COVID-19}}=0.006$, 95% CI = $-0.011$–$0.024$; $\beta_{\text{Hospitalized COVID-19}}=0.007$, 95% CI = $-0.012$–$0.027$; $\beta_{\text{Hospitalized COVID-19}}=0.007$, 95% CI = $-0.013$–$0.028$; $\beta_{\text{Hospitalized COVID-19}}=0.004$, 95% CI = $-0.028$–$0.018$; $\beta_{\text{Hospitalized COVID-19}}=0.006$, 95% CI = $-0.004$–$0.016$; $\beta_{\text{Hospitalized COVID-19}}=0.003$, 95% CI = $-0.02$–$0.031$; $\beta_{\text{Hospitalized COVID-19}}=0.001$, 95% CI = $-0.017$–$0.040$; $\beta_{\text{Hospitalized COVID-19}}=0.009$, 95% CI = $-0.008$–$0.026$; $\beta_{\text{COVID-19 infection}}=0.015$, 95% CI = $-0.053$–$0.083$; $\beta_{\text{COVID-19 infection}}=0.016$, 95% CI = $-0.057$–$0.090$; Supplementary Table S4 and Supplementary Figures S7–S9, available as Supplementary data at IJE online). For the MR tests evaluating the effect of COVID-19 on anthropometric traits using genome-wide significant variants, the F-statistic ranged from 0.002 to 0.045 (available as Supplementary data at IJE online).

In the MR analysis based on suggestive variants (all LD-independent variants available from the top 10,000 variants released from the COVID HGI meta-analysis including 23andMe data), the leave-one-out tests indicated the presence of major outliers. After their removal, we found no evidence of a possible causal effect of COVID-19 on anthropometric traits for most of the tested associations (Supplementary Figures S11 and S13, available as Supplementary data at IJE online) except for an effect of genetically determined hospitalized COVID-19 on HIP ($\beta=0.02$, 95% CI = $0.01$–$0.04$, $P=0.002$; Supplementary Figure S12, available as Supplementary data at IJE online). However, the effect size is much smaller than that observed in the reverse direction ($\beta_{\text{Hospitalized COVID-19}}=0.02$ vs $\beta_{\text{HIP}}=0.01$). Additionally, we found evidence of strong heterogeneity within the genetic instruments evaluated that decreased after the removal of several outliers identified in the leave-one-out analysis. Since the leave-one-out analysis did not indicate the presence of additional major outliers, we hypothesized that the heterogeneity observed could be the result of the widespread pleiotropy among the variants included in the genetic instruments. Thus, we re-estimated the effects using the MR–RAPS approach with using squared error loss method ($\tilde{I}^2$) to account for overdispersion (systematic pleiotropy) within the genetic instrument.\textsuperscript{37} The result observed was consistent with the IVW estimates ($\beta=0.01$, 95% CI = $0.004$–$0.0105$, $P=0.02$) (Supplementary Figure 1 and Supplementary Table S5, available as Supplementary data at IJE online). For the MR tests evaluating the effect of COVID-19 on anthropometric traits using suggestive variants, the F-statistic ranged from 11.90 to 20.37, and $R^2$ ranged from 0.0002 to 0.03 (Supplementary Table S5, available as Supplementary data at IJE online). The overlap of the LD-independent SNPs associated with the COVID-19 phenotypes using suggestive variants is shown in Supplementary Figure S10 (available as Supplementary data at IJE online).

To test whether the effect of anthropometric traits on COVID-19 is independent of SES, we initially verified the reliability of the income genetic instrument using the univariate MR approach. There was a protective effect of income on severe respiratory COVID-19 (OR = 0.70, 95% CI = 0.53–0.93, $P=0.015$) and hospitalized COVID-19 (OR = 0.78, 95% CI = 0.66–0.92, $P=0.003$; Supplementary Figure S14, available as Supplementary data at IJE online). No causal association of income on COVID-19 infection was found (OR = 0.95, 95% CI = 0.89–1.01, $P=0.108$). These estimates were not affected by heterogeneity or horizontal pleiotropy (Supplementary Table S6, available as Supplementary data at IJE online). These results were consistent with the estimates observed using the COVID-19 HGI Release 5 data based only on individuals of European descent (Supplementary Table S2, available as Supplementary data at IJE online). For the MR tests evaluating the effect of income on COVID-19 outcomes, the F-statistic ranged from 40.88 to 41.83, and $R^2$ ranged from 0.0008 to 0.045 (Supplementary Table S6, available as Supplementary data at IJE online).

Because the UK Biobank cohort was included in both income and COVID-19 GWAS, we verified that this sample overlap did not affect the estimates observed. Using COVID-19 HGI meta-analysis excluding the UK Biobank sample, we observed no statistical difference in the effect size of the associations observed with respect to the analyses obtained using the COVID-19 HGI meta-analyses including the UK Biobank sample (Supplementary Table S7, available as Supplementary data at IJE online). Neither the MR analysis with genome-wide significant variants nor that with suggestive variants (top 10,000) indicate an effect of COVID-19 phenotypes on income (Supplementary Table S8 and S9 and Supplementary Figures S16 and S17, available as Supplementary data at IJE online). For the MR tests evaluating the effect of COVID-19 on income using genome-wide variants, the F-statistic ranged from 81.95 to 89.38, and $R^2$ ranged from 0.04 to 0.28 (Supplementary Table S8, available as Supplementary data
at *IJE* online), whereas for the MR tests using suggestive variants, the F-statistic ranged from 13.78 to 17.29, and $R^2$ ranged from 0.0001 to 0.001 (Supplementary Table S9, available as Supplementary data at *IJE* online). The overlap of exposure SNPs using genome-wide and suggestive variants are shown in Supplementary Figure S15 (available as Supplementary data at *IJE* online).

In the MVMR, the effect of the anthropometric traits on severe respiratory COVID-19 (i.e. BMI and WC) and hospitalized COVID-19 (i.e. BMI, WC and HIP) was null when accounting for the effect of income (Figure 2 and Supplementary Tables S10 and S11, available as Supplementary data at *IJE* online). Conversely, the effect of income on severe respiratory COVID-19 and hospitalized COVID-19 was not affected when accounting for each anthropometric trait individually and including all anthropometric traits in the same MVMR model (Supplementary Tables S10–S12, available as Supplementary data at *IJE* online). The income genetic instruments did not overlap with those from the anthropometric traits, as shown in Supplementary Figures S18 and S19 (available as Supplementary data at *IJE* online).

We found an effect of income on anthropometric traits (Figure 3A, Supplementary Figure S20 and Supplementary Table S13, available as Supplementary data at *IJE* online). A 1-SD increase in income was associated with lower odds of BMI (kg/m$^2$; $OR = 0.91$, 95% CI = 0.86–0.97, $P = 0.006$), WC (cm; $OR = 0.91$, 95% CI = 0.85–0.98, $P = 0.012$) and WHR (OR = 0.89, 95% CI = 0.83–0.94, $P = 0.0002$). Also, we found evidence of a positive effect of income on BMI-adjusted HIP (cm; $OR = 1.10$, 95% CI = 1.02–1.17, $P = 0.006$). For the MR tests evaluating the effect of income on anthropometric traits, the F-statistic ranged from 39.70 to 41.77, and $R^2$ ranged from 0.002
We found effects of genetically determined anthropometric traits on income (Figure 3B, Supplementary Table S14 and Supplementary Figure S22, available as Supplementary data at IJE online). We found that 1-SD increases in BMI, WC, HIP and BMI-adjusted WHR were associated with lower odds of income (BMI: OR = 0.94,
95% CI = 0.90–0.97, \( P = 0.0015 \); WC: OR = 0.93, 95% CI = 0.88–0.98, \( P = 0.0008 \); HIP: OR = 0.95, 95% CI = 0.91–0.98, \( P = 0.007 \); BMI-adjusted WHR: OR = 0.94, 95% CI = 0.90–0.98, \( P = 0.007 \). These estimates were not affected by heterogeneity or horizontal pleiotropy (Supplementary Table S14, available as Supplementary data at IJE online). For the MR tests evaluating the effect of anthropometric traits on income, the F-statistic ranged from 48.01 to 66.73, and \( R^2 \) ranged from 0.001 to 0.59 (Supplementary Table S14, available as Supplementary data at IJE online). The overlap of genetic instruments is shown in Supplementary Figure S21 (available as Supplementary data at IJE online). There were no differences between the effect size estimates in the bidirectional relationship between income and the anthropometric traits investigated (Supplementary Table S15, available as Supplementary data at IJE online).

Through a MVMR analysis, we demonstrated that the effects of the anthropometric traits on income were not independent from each other (BMI: OR = 1.02, 95% CI = 0.85–1.22, \( P = 0.799 \); WC: OR = 1.32, 95% CI = 0.73–2.40, \( P = 0.347 \); HIP: OR = 0.71, 95% CI = 0.46–1.11, \( P = 0.14 \); BMI-adjusted WHR: OR = 0.82, 95% CI = 0.60–1.13, \( P = 0.229 \); Supplementary Table S16, available as Supplementary data at IJE online).

Discussion

The association of obesity-related traits with COVID-19 outcomes has been confirmed by multiple studies, also including MR analyses that showed putative causal effects of BMI, \( \delta^{11,48,49} \) WC, \( \delta^{9,10} \) and trunk fat ratio. \( \delta^{9} \) Some of these previous investigations also have included MVMR analyses that highlighted how the effect of these traits on COVID-19 is independent of several cardiometabolic traits and other known risk factors. \( \delta^{9} \) However, to our knowledge, no study has evaluated whether the effect of obesity-related traits on COVID-19 outcomes is independent of SES. Because of the unprecedented impact of COVID-19 on individuals and society, it is crucial to identify individuals at risk and relevant modifiable factors to reduce COVID-19 morbidity and mortality. Current findings support that traits related to body size should be among the primary targets to prevent COVID-19 severe symptoms. \( \delta^{50} \) However, there is a well-established relationship between body size variation and SES that may affect the associations observed. \( \delta^{51} \)

The results of our univariable MR analysis showed positive associations between genetically determined BMI with COVID-19 outcomes. These findings are consistent with previous reports of a causal impact of BMI on severe respiratory and hospitalized COVID-19. \( \delta^{9,11,48,49} \) However, our multivariable analysis indicated that these associations are affected by the effect of SES on COVID-19 outcomes. Specifically, whereas the association of obesity-related traits with COVID-19 severity and hospitalization becomes null when accounting for SES, the effect of income on COVID-19 outcomes becomes stronger when accounting for anthropometric traits. With respect to the latter result, we hypothesize that accounting for the effect of anthropometric traits reduces the phenotypic heterogeneity of COVID-19 outcomes, increasing the accuracy of the estimates of the association of income.

Overall, our findings have major public health implications because whereas previous studies highlighted the importance of considering obesity among the risk factors associated with COVID-19 severe outcomes, our results strongly highlight that this evidence should be put in the context of the effect of SES on both body size and COVID-19. The mechanisms by which income is affecting the association between obesity-related anthropometric traits and COVID-19 might be similar to those proposed for other known health outcomes. In general, low-income populations have reduced access to medical care, with subsequent worse health at baseline and lower opportunity to receive adequate treatment to health complications in comparison with high-income groups. \( \delta^{52,53} \) Finally, these healthcare inequalities are translated into a higher morbidity and mortality risk in communities with a lower household income. \( \delta^{54} \)

Nevertheless, we observed a bidirectional relationship between income and the anthropometric traits investigated. This suggests a complex interplay between these traits. In this regard, it has been reported that individuals with a lower SES generally have a higher BMI and an increased risk of obesity. \( \delta^{15} \) There are multiple social and environmental factors contributing to the association between SES and BMI, i.e. economic difficulties, the affordability of energy-dense foods, low dietary quality, poor health literacy, occupational status and lifestyle behaviours, such as low physical activity and sedentary behaviours. \( \delta^{55–60} \) There is also evidence that obesity-related traits can affect SES via multiple factors that have been previously grouped into three categories: \( \delta^{61} \) (i) health effects: high BMI increases the risk of several chronic diseases, which could affect work ability and subsequently income; \( \delta^{61,62} \) (ii) reduced job performance: body shape affects health capital, presenteeism, self-esteem and employment status, which impact income; \( \delta^{63,64} \) (iii) discrimination from employers. \( \delta^{65,66} \) Accordingly, there are likely multiple pathways by which income could affect the association between obesity-related traits and COVID-19 outcomes. Although our MVMR analysis clearly shows that the effect of obesity-related traits on COVID-19 outcomes is not
independent of the income effect, the bidirectional relationship between anthropometric traits and income does not permit us to make a hypothesis regarding the temporal relationship between the exposures investigated.

Furthermore, factors influencing both SES and obesity that also act as modulators of their association in both directions have been identified, such as sex, ethnicity, country’s income economy and education. For example, in developed countries, obesity is more prevalent in individuals with lower SES, whereas in developing countries there is not a clear trend. Despite the relevance of the mentioned environmental and social factors, it is important to consider that obesity is a complex multifactorial disease influenced by both environmental and genetic factors, as well as by the interaction between them.

Similarly to obesity, there is evidence of the effect of genetic factors on SES, particularly on income. The genetic variants associated with a higher income were functionally linked with GABAergic and serotonergic neurotransmission and linked to cognitive abilities. In our genetically-informed study, we found that income had a negative causal effect on both very severe respiratory confirmed COVID-19 and hospitalized COVID-19. Previously, a longitudinal study reported a negative relationship between income and COVID-19 mortality, which might be considered an extreme COVID-19 phenotype. Interestingly, there was no difference in COVID-19 infection rate among the different income groups. Hence, these previous results and ours suggest that income influences only COVID-19 severe phenotypes. Further exploration of the genetic variants involved in this association might provide information on their biological role in the predisposition to COVID-19 complications. The elucidation of the mechanisms will contribute to the design of strategies and/or treatments that could modulate their effect on COVID-19 outcomes. The mechanisms linking the genetic predisposition to obesity and COVID-19 are likely to be multifactorial and warrant clarification in further research.

Overall, the anthropometric traits evaluated here showed a consistent effect on COVID-19 phenotypes. However, this association is not direct and multiple factors might affect these associations, i.e. health behaviours associated with SES such as physical inactivity, diet and tobacco and alcohol use. Although the results of the reverse MR might suggest an effect of genetically predicted COVID-19 phenotypes on anthropometric traits and SES, the effect size is negligible, suggesting a possible residual effect of horizontal pleiotropy. The identification of factors underlying these causal associations will contribute to the design of adequate risk-stratification instruments for patients with COVID-19. Furthermore, it might contribute on a higher scale to the design of public policies oriented to the prevention of adverse outcomes in vulnerable groups. Although these public policies will not modify the genetic factors involved in the development of severe COVID-19 symptoms, they might impact modifiable risk factors and reduce social inequalities. For example, strategies that improve the access to adequate medical services might lead to the adverse impact of COVID-19 in low-income communities.

The limitations of the present study should be acknowledged. First, this study was conducted using data generated from participants of European descent. Accordingly, the results obtained may not be generalization to populations with other ancestral origins. Further research is necessary to evaluate the effect of anthropometric and socio-economic traits in populations with diverse ancestral backgrounds. Second, we could not evaluate the presence of sex-specific effects as large-scale data sets informative of sex-specific COVID-19 susceptibility are not available at this time. There are known sex differences in the mechanisms underlying the association of SES with body size and composition. Therefore, future sex-stratified studies are required to understand the processes linking these traits with COVID-19 outcomes. Third, although we conducted multiple sensitivity analyses, we cannot discard completely the influence of potential confounders in our results. Therefore, complementary studies are needed to confirm and further explore the findings here reported. Also, in this study, we selected income to measure SES as it has shown a higher association with health when adjusted for other SES variables, i.e. education, social class and occupational complexity. Thus, we considered income as a SES dimension particularly relevant for studying health-related associations such as those evaluated in the present study. Furthermore, the income GWAS identified genetic variants that are associated with partly heritable traits (e.g. intelligence, conscientiousness and health outcomes) that are linked to income but do not act directly on it. Future studies will determine the role of other SES dimensions in the association between anthropometric traits and COVID-19 outcomes.

Furthermore, we acknowledge some limitations in the MVMR approach. First, although MR estimates mostly represent the lifetime effect of the exposure on the outcome, there may be exceptions due to time-varying exposures. Specifically, although genetic variants do not vary over an individual’s lifetime, variation could arise from different genetic variants having different levels of importance in the development of the exposure at different times. Second, whereas an interaction between the two exposures does not affect the direct effects of the exposure included in the MVMR model, an interaction between
exposure can affect MVMR models investigating possible mediation pathways. \(^7\) We observed a bidirectional relationship between income and anthropometric traits. Thus, we cannot discard the presence of an interplay between income and anthropometric traits. Further studies are required to investigate the pathways underlying the association of SES and obesity-related traits with COVID-19 outcomes.

In conclusion, we provide the first evidence that the relationship of obesity-related anthropometric traits with COVID-19 outcomes is not independent of SES. This result has major public health implications because it supports that preventive strategies targeting body size and composition to reduce COVID-19 morbidity and mortality may not be effective if they are not considered in the context of SES.

**Ethics approval**

This study was conducted using genome-wide association statistics generated by previous studies. Owing to the use of previously collected, de-identified, aggregated data, this study did not require institutional review board approval.

**Data availability**

The data sets used in this study are available on the GIANT consortium website (http://portals.broadinstitute.org/collaboration/giant/index.php/GIANT_consortium), the COVID-19 Host Genetics Initiative website (https://www.covid19hg.org/) and the UK Biobank website (https://www.ukbiobank.ac.uk/). All data discussed in this study are provided in the article and in the Supplementary material.

**Supplementary data**

Supplementary data are available at IJE online.

**Author contributions**

B.C.M. and R.P. participated in the concept and design of the study, statistical analysis and drafting of the manuscript, and have verified the underlying data. B.C.M., F.R.W., G.A.P., F.D.A., A.D.L., D.K. and R.P. participated in the acquisition, analysis and interpretation of data and critical revision of the manuscript for important intellectual content. F.R.W., D.K. and R.P. obtained the funding for this study. F.R.W., G.A.P., F.D.A., A.D.L., D.K. and R.P. provided the administrative, technical and material support for this study. R.P. supervised the present study. All the authors revised and approved the final version of this manuscript.

**Funding**

This work was supported by the National Institutes of Health (R21 DC018098, R33 DA047527, F32 MH122058) and the European Commission (H2020 Marie Skłodowska-Curie Individual Fellowship 101028810).

**Acknowledgements**

We thank study participants and research groups contributing to the GIANT consortium, UK Biobank and the COVID-19 HGI for making their data available.

**Conflict of interest**

None declared.

**References**

1. Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review. JAMA 2020; 324:782.
2. World Health Organization (WHO) Coronavirus (COVID-19) Dashboard https://covid19.who.int (8 February 2022, date last accessed).
3. Chen N, Zhou M, Dong X et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020;395:507–13.
4. Epidemiology Working Group for NCIP Epidemic Response, Chinese Center for Disease Control and Prevention. [The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China]. Zhonghua Liu Xing Bing Xue Za Zhi 2020;41:145–51.
5. Kalligeros M, Shehadeh F, Mylona EK et al. Association of obesity with disease severity among patients with coronavirus disease 2019. Obesity (Silver Spring) 2020;28:1200–04.
6. Lighter J, Phillips M, Hochman S et al. Obesity in patients younger than 60 years is a risk factor for COVID-19 hospital admission. Clin Infect Dis 2020;71:896–97.
7. Palaiodimos L, Kokkinidis DG, Li W et al. Severe obesity, increasing age and male sex are independently associated with worse in-hospital outcomes, and higher in-hospital mortality, in a cohort of patients with COVID-19 in the Bronx, New York. Metabolism 2020;108:154262.
8. Simonnet A, Chetboun M, Poissy J et al.; LICORN and the Lille COVID-19 and Obesity study group. High prevalence of obesity in severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) requiring invasive mechanical ventilation. Obesity (Silver Spring) 2020;28:1195–99.
9. Freuer D, Linseisen J, Meisinger C. Impact of body composition on COVID-19 susceptibility and severity: a two-sample multivariable Mendelian randomization study. Metabolism 2021; 118:154732.
10. Aung N, Khanji MY, Munroe PB, Petersen SE. Causal inference for genetic obesity, cardiometabolic profile and COVID-19 susceptibility: a Mendelian randomization study. Front Genet 2020;11:586308.
11. Li S, Hua X. Modifiable lifestyle factors and severe COVID-19 risk: a Mendelian randomisation study. BMC Med Genomics 2021;14:38.
12. Kivimäki M, Batty GD, Pentti J et al. Association between socioeconomic status and the development of mental and physical...
13. Bilal U, Caiminos-Achirica M, Clerries M et al. Socioeconomic status, life expectancy and mortality in a universal healthcare setting: an individual-level analysis of >6 million Catalan residents. *Prev Med* 2019;123:91–94.

14. Howe LD, Kanayalal R, Harrison S et al. Effects of body mass index on relationship status, social contact and socio-economic position: Mendelian randomization and within-sibling study in UK Biobank. *Int J Epidemiol* 2020;49:1173–84.

15. McLaren L. Socioeconomic status and obesity. *Epidemiol Rev* 2007;29:29–48.

16. Tyrrell J, Jones SE, Beaumont R et al. Height, body mass index, and socioeconomic status: mendelian randomisation study in UK Biobank. *BMJ* 2016;352:i582.

17. Bentley RA, Ormerod P, Ruck DJ. Recent origin and evolution of obesity-income correlation across the United States. *Palgrave Commun* 2018;4:146.

18. Hawkins RB, Charles EJ, Mehaffey JH. Socio-economic status and COVID-19-related cases and fatalities. *Public Health* 2020;189:129–34.

19. Consolazio D, Murtas R, Tunesi S, Gervasi F, Benassi D, Russo AG. Assessing the impact of individual characteristics and neighborhood socioeconomic status during the COVID-19 pandemic in the provinces of Milan and Lodi. *Int J Health Serv* 2021;51:311–24.

20. Harrison S, Davies AR, Dickson M et al. The causal effects of health conditions and risk factors on social and socioeconomic outcomes: Mendelian randomization in UK Biobank. *Int J Epidemiol* 2020;49:1661–81.

21. Muniz Carvalho C, Wendt FR, Maihofer AX et al. Dissecting the genetic association of C-reactive protein with PTSD, traumatic events, and social support. *Neuropsychopharmacology* 2021;46:1071–77.

22. Polimanti R, Ratnatharathorn A, Maihofer AX et al.; Psychiatric Genomics Consortium Posttraumatic Stress Disorder Working Group. Association of economic status and educational attainment with posttraumatic stress disorder: a Mendelian randomization study. *JAMA Netw Open* 2019;2:e193447.

23. GIANT consortium—GIANT Consortium. http://portals.broadinstitute.org/collaboration/giant/index.php/GIANT_consortium (3 February 2022, date last accessed).

24. The LifeLines Cohort Study, The ADIPOGen Consortium, The AGEN-BMI Working Group, The CARDIOGRAMplusC4D Consortium, The CKDGen Consortium, The GLGC et al. Genetic studies of body mass index yield new insights for obesity biology. *Nature* 2015;518:197–206.

25. The CKDGen Consortium, The GEFOSS Consortium, The GENIE Consortium, The GLGC et al.; The ADIPOGen Consortium, the CARDIOGRAMplusC4D Consortium. New genetic loci link adipose and insulin biology to body fat distribution. *Nature* 2015;518:187–96.

26. Davies NM, Holmes MV, Davey Smith G. Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians. *BMJ* 2018;362:k601.

27. COVID-19 Host Genetics Initiative. Mapping the human genetic architecture of COVID-19. *Nature* 2021;600:472–77.

28. The COVID-19 Host Genetics Initiative. The COVID-19 Host Genetics Initiative, a global initiative to elucidate the role of host genetic factors in susceptibility and severity of the SARS-CoV-2 virus pandemic. *Eur J Hum Genet* 2020;28:715–18.

29. Bycroft C, Freeman C, Petkova D et al. The UK Biobank resource with deep phenotyping and genomic data. *Nature* 2018;562:203–09.

30. Hill WD, Davies NM, Ritchie SJ et al. Genome-wide analysis identifies molecular systems and 149 genetic loci associated with income. *Nat Commun* 2019;10:5741.

31. Burgess S, Foley CN, Allara E, Staley JR, Howson JMM. A robust and efficient method for Mendelian randomization with hundreds of genetic variants. *Nat Commun* 2020;11:376.

32. Verbanck M, Chen C-Y, Neale B, Do R. Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases. *Nat Genet* 2018;50:693–98.

33. Liao L, Li W, Liu Y, Li J, Zhuang X, Liao X. Exploring the causal pathway from omega-6 levels to coronary heart disease: a network Mendelian randomization study. *Nutr Metab Cardiovasc Dis* 2020;30:233–40.

34. Sanderson E, Davey Smith G, Windmeijer F, Bowden J. An examination of multivariable Mendelian randomization in the single-sample and two-sample summary data settings. *Int J Epidemiol* 2019;48:713–27.

35. Hemani G, Zheng J, Elsworth B et al. The MR-Base platform supports systematic causal inference across the human phenoome. *eLife* 2018;7:e34408.

36. Auton A, Brooks LD, Durbin RM, et al.; 1000 Genomes Project Consortium. A global reference for human genetic variation. *Nature* 2015;526:68–74.

37. Hemani G, Bowden J, Davey Smith G. Evaluating the potential role of pleiotropy in Mendelian randomization studies. *Hum Mol Genet* 2018;27:R195–208.

38. Hartwig FP, Davey Smith G, Bowden J. Robust inference in summary data Mendelian randomization via the zero modal pleiotropy assumption. *Int J Epidemiol* 2017;46:1985–98.

39. Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. *Int J Epidemiol* 2015;44:512–25.

40. Burgess S, Bowden J, Fall T, Ingelsson E, Thompson SG. Sensitivity analyses for robust causal inference from Mendelian randomization analyses with multiple genetic variants. *Epidemiology* 2017;28:30–42.

41. Guo Y, Lu Y, Jin H. Appraising the role of circulating concentrations of micro-nutrients in epithelial ovarian cancer risk: a Mendelian randomization analysis. *Sci Rep* 2020;10:7356.

42. Fluharty ME, Sallis H, Munafò MR. Investigating possible causal effects of externalizing behaviors on tobacco initiation: a Mendelian randomization analysis. *Drug Alcohol Depend* 2018;191:338–42.

43. Sterne JA, Davey Smith G. Sifting the evidence—what’s wrong with significance tests? *BMJ* 2001;322:226–31.

44. Zhao Q, Wang J, Hemani G, Bowden J, Small DS. Statistical inference in two-sample summary-data Mendelian randomization using robust adjusted profile score. *Ann Statist* 2020;48:1742–69.

45. Burgess S, Thompson SG. Multivariable Mendelian randomization: the use of pleiotropic genetic variants to estimate causal effects. *Am J Epidemiol* 2015;181:251–60.
46. Zuber V, Colijn JM, Klaver C, Burgess S. Selecting likely causal risk factors from high-throughput experiments using multivariable Mendelian randomization. Nat Commun 2020;11:29.

47. Gao C-H, Yu G, Cai P. ggVennDiagram: an intuitive, easy-to-use, and highly customizable R package to generate Venn diagrams. Front Genet 2021;12:706907.

48. Ponsford MJ, Gkatzionis A, Walker YM et al. Cardiometabolic traits, sepsis, and severe COVID-19: a Mendelian randomization investigation. Circulation 2020;142:1791–93.

49. Leong A, Cole JB, Brenner LN, Meigs JB, Florez JC, Mercader JM. Cardiometabolic risk factors for COVID-19 susceptibility and severity: a Mendelian randomization analysis. Theriault S, editor. PLoS Med 2021;18:e1003553.

50. Dietz W, Santos-Burgoa C. Obesity and its implications for COVID-19 mortality. Obesity (Silver Spring) 2020;28:1005.

51. Gradidge PJ-L, Norris SA, Munthali R, Crowther NJ. Influence of socioeconomic status on changes in body size and physical activity in ageing black South African women. Eur Rev Aging Phys Act 2018;15:6.

52. Apenyo T, Vera-Urbina A, Ahmad K, Taveira TH, Wu W-C, McMaughan DJ, Oloruntoba O, Smith ML. Socioeconomic status, urbanisation, and lifestyle patterns. Int J Obes 2016;40:1794–801.

53. Bates B, Collins D, Cox L et al. National Diet and Nutrition Survey Years 1 to 9 of the Rolling Programme (2008/2009–2016/2017): Time Trend and Income Analyses. London: Public Health England, 2019. http://www.gov.uk/phe (3 February 2022, date last accessed).

54. Ritter A, Kreis N-N, Louwen F, Yuan J. The overweight and obesity transition from the wealthy to the poor in low- and middle-income countries: a survey of household data from 103 countries. PLoS Med 2019;16:e1002968.

55. Ogden CL, Lamb MM, Carroll MD, Flegal KM. Obesity and socio-economic status in adults: United States, 2005–2008. NCHS Data Brief 2010;50:1–8.

56. Ogden CL, Lamb MM, Carroll MD, Flegal KM. Obesity and socio-economic status in adults: United States, 2005–2008. NCHS Data Brief 2010;50:1–8.

57. Adams J. Addressing socioeconomic inequalities in obesity: democratising access to resources for achieving and maintaining a healthy weight. PLoS Med 2020;17:e1003243.

58. Hanson MD, Chen E. Socioeconomic status, race, and body mass index: the mediating role of physical activity and sedentary behaviors during adolescence. J Pediatr Psychol 2006;32:220–30.

59. Sodjinou R, Agueh V, Fayomi B, Delisle H. Obesity and cardiometabolic risk factors in urban adults of Benin: relationship with socio-economic status, urbanisation, and lifestyle patterns. BMC Public Health 2008;8:84.

60. Wardle J, Waller J, Jarvis MJ. Sex differences in the association of socioeconomic status with obesity. Am J Public Health 2002;92:1299–304.

61. Edwards CH, Bjørngaard JH, Minet Kinje J. The relationship between body mass index and income: using genetic variants from HUNT as instrumental variables. Health Econ 2021;30:1933–49.

62. Larsson SC, Burgess S. Role of high body mass index in multiple chronic diseases: a systematic review and meta-analysis of Mendelian randomization studies. BMC Med 2021;19:320.

63. Ku B, Phillips KE, Fitzpatrick JJ. The relationship of body mass index (BMI) to job performance, absenteeism and risk of eating disorder among hospital-based nurses. Appl Nurs Res 2019;49:77–79.

64. Sanchez Bustillos A, Vargas KG, Gomez-Cuadra R. Work productivity among adults with varied Body Mass Index: results from a Canadian population-based survey. J Epidemiol Glob Health 2015;5:191–99.

65. Campbell DD, Green M, Davies N et al. Effects of increased body mass index on employment status: a Mendelian randomisation study. Int J Obes (Lond) 2021;45:1790–801.

66. Latner JD, Barile JP, Durso LE, O’Brien KS. Weight and health-related quality of life: the moderating role of weight discrimination and internalized weight bias. Eat Behav 2014;15:586–90.

67. Dinsa GD, Goryakin Y, Fumagalli E, Suhrecker M. Obesity and socioeconomic status in developing countries: a systematic review. Obes Rev 2012;13:1067–79.

68. Templin T, Cravo Oliveira Hashiguchi T, Thomson B, Dieleman JL, Benavidez E. The overweight and obesity transition from the wealthy to the poor in low- and middle-income countries: a survey of household data from 103 countries. PLoS Med 2019;16:e1002968.

69. Ogden CL, Lamb MM, Carroll MD, Flegal KM. Obesity and socioeconomic status in adults: United States, 2005–2008. NCHS Data Brief 2010;50:1–8.

70. Tzaskowski M, Harlaar N, Arden R et al. Genetic influence on family socioeconomic status and children’s intelligence. Intelligence 2014;42:83–88.

71. Marioni RE, Davies G, Hayward C et al. Molecular genetic contributions to socioeconomic status and intelligence. Intelligence 2014;44:26–32.

72. Zhu Z, Hasegawa K, Ma B, Fujiogi M, Camargo CA, Liang L. Cardiometabolic risk factors for COVID-19 susceptibility and severity: a Mendelian randomization analysis. Theriault S, editor. PLoS Med 2021;18:e1003553.

73. Stringhini S, Sabia S, Shipley M et al. Association of obesity and its genetic predisposition with the risk of severe COVID-19: analysis of population-based cohort data. Metabolism 2020;112:154345.

74. Cambi SM, Bray GA, Bouchard C et al. The relationship of waist circumference and BMI to visceral, subcutaneous, and total body fat: sex and race differences. Obesity (Silver Spring) 2011;19:402–08.

75. Darin-Mattsson A, Fors S, Kåreholt I. Different indicators of socioeconomic status and their relative importance as determinants of health in old age. Int J Equity Health 2017;16:173.

76. Hill WD, Hagenaaars SP, Marioni RE et al. Molecular genetic contributions to social deprivation and household income in UK biobank. Curr Biol 2016;26:3083–89.

77. Labrecque JA, Swanson SA. Interpretation and potential biases of Mendelian randomization estimates with time-varying exposures. Am J Epidemiol 2019;188:231–38.

78. Sanderson E, Richardson TG, Morris TT, Tilling K, Smith GD. Estimation of causal effects of a time-varying exposure at multiple time points through Multivariable Mendelian randomization. medRxiv; doi:10.1101/2022.01.04.22268740, January 05, 2022, preprint: not peer reviewed.

79. Carter AR, Sanderson E, Hammerton G et al. Mendelian randomisation for mediation analysis: current methods and challenges for implementation. Eur J Epidemiol 2021;36:465–78.